LAW OFFICES

HYMAN, PHELPS & MCNAMARA, P.C.

KURT R. KARST

700 THIRTEENTH STREET, N.W.
SUITE 1200
WASHINGTON, D.C. 20005-5929
(202) 737-5600
FACSIMILE

Direct Dial (202) 737-7544 kkarst@hpm.com

(202) 737-9329

www.hpm.com

August 3, 2022

BY ELECTRONIC SUBMISSION

Division of Dockets Management Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 (HFA-305) Rockville, MD 20852

RE: Docket No. FDA-2022-P-0329; Withdrawal

Dear Sir or Madam:

The undersigned Petitioner hereby withdraws the Citizen Petition, dated March 10, 2022, requesting that FDA assign in the Agency's Orange Book a Therapeutic Equivalence Code of "AP" to the 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL, drug products approved under NDA 215395 for InvaGen's Lanreotide Injection.

Sincerely,

Kurt R. Karst

KRK/eam